Anebulo Pharmaceuticals (214) Stock Statistics & Valuation Metrics
Total Valuation
Anebulo Pharmaceuticals has a market cap or net worth of EUR 8.80M. The enterprise value is EUR 32.45M.
- Market Cap
- EUR 8.80M
- Enterprise Value
- EUR 32.45M
Share Statistics
Anebulo Pharmaceuticals has 40,784,733 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 40,784,733
- Owned by Insiders
- ―
- Owned by Institutions
- 51.73%
Financial Efficiency
Anebulo Pharmaceuticals’s return on equity (ROE) is -0.73 and return on invested capital (ROIC) is -77.37%.
- Return on Equity (ROE)
- -0.73
- Return on Assets (ROA)
- -0.70
- Return on Invested Capital (ROIC)
- -77.37%
- Return on Capital Employed (ROCE)
- -0.77
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.83M
- Employee Count
- 3
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Anebulo Pharmaceuticals is -1.58. Anebulo Pharmaceuticals’s PEG ratio is -0.04.
- PE Ratio
- -1.58
- PS Ratio
- 0.00
- PB Ratio
- 1.25
- Price to FCF
- -2.33
- Price to Operating Cash Flow
- -2.35
- PEG Ratio
- -0.04
Income Statement
In the last 12 months, Anebulo Pharmaceuticals had revenue of 0 and earned -8.48M in profits. Earnings per share was -0.25.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -9.22M
- Pretax Income
- -8.48M
- Net Income
- -8.48M
- EBITDA
- -7.72M
- Earnings Per Share (EPS)
- -0.25
Cash Flow
In the last 12 months, operating cash flow was -5.84M and capital expenditures 0, giving a free cash flow of -5.84M billion.
- Operating Cash Flow
- -5.84M
- Free Cash Flow
- -5.84M
- Free Cash Flow per Share
- -0.10
Dividends & Yields
Anebulo Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -42.94%
- Earnings Yield
- -63.39%
Stock Price Statistics
- Beta
- -2.47
- 52-Week Price Change
- -80.27%
- 50-Day Moving Average
- 0.43
- 200-Day Moving Average
- 0.50
- Relative Strength Index (RSI)
- 29.57
- Average Volume (3m)
- ―
Important Dates
Anebulo Pharmaceuticals upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Sep 23, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Anebulo Pharmaceuticals as a current ratio of 53.36, with Debt / Equity ratio of 0.00%
- Current Ratio
- 53.36
- Quick Ratio
- 53.36
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.51
- Interest Coverage Ratio
- -24.14
Taxes
In the past 12 months, Anebulo Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Anebulo Pharmaceuticals EV to EBITDA ratio is -0.13, with an EV/FCF ratio of -0.20.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.13
- EV to Free Cash Flow
- -0.20
- EV to Operating Cash Flow
- -0.20
Balance Sheet
Anebulo Pharmaceuticals has EUR 9.04M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 9.04M billion.
- Cash & Marketable Securities
- EUR 9.04M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 9.04M
- Net Cash Per Share
- EUR 0.22
- Tangible Book Value Per Share
- EUR 0.19
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%